KOSDAQFood & Beverage267980

Maeil Dairies

₩34,900▲ 2.95%2026-11-18 close
Market Cap
₩267.5B
Turnover
₩100M
Volume
4.3K
Shares out.
7.7M
PER
4.1×
PBR
0.4×
EPS
₩8,284
Dividend Yield
3.82%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,300 per share · Prices as of the 2026-11-18 close

01

Report overview

Maeil Dairies: Profit Recovery Led by Nutrition and Fermented Milk

Despite losses in white milk and higher input costs, Maeil Dairies' sales and operating profit rose for three straight quarters through the third quarter of 2026, while net profit attributable to controlling shareholders fell for two consecutive quarters.

  1. 1

    Third-quarter 2026 sales reached KRW 493.7 billion and operating profit KRW 22.2 billion, up 4.7% and 11.6% year on year.

  2. 2

    Net profit attributable to controlling shareholders was KRW 9.8 billion in the same quarter, down 38.6% year on year, moving in the opposite direction from operating profit.

  3. 3

    Operating profit peaked at KRW 72.2 billion in 2023 and fell to KRW 60 billion in 2025, when the operating margin of 3.3% was the lowest of 2022 to 2025.

  4. 4

    The Nutrition segment grew to KRW 194.2 billion in sales for the first three quarters of 2026, up 15.7%, though its third-quarter operating profit alone fell 10.2% to KRW 2.8 billion.

  5. 5

    The next periodic report is the 2026 annual report, and the size of white milk losses and the direction of quarterly Nutrition profit are the key points to track.

02

Business structure

Maeil Dairies manufactures, sells and imports and exports dairy products and beverages.

Its 2023 annual business report split operations into a dairy processing segment and an other segment, with dairy processing (white milk, infant formula and fermented milk) at 61.52% of sales and other products (coffee, juice, grain drinks) at 38.48%.

The third-quarter 2026 disclosures show three segments: dairy processing, Nutrition and other. Third-quarter 2026 segment sales were reported at KRW 252.4 billion for dairy processing, KRW 73.7 billion for Nutrition and KRW 167.6 billion for other products.

Nutrition accounted for about 14.9% of third-quarter sales, and its sales for the first three quarters of 2026 reached KRW 194.2 billion, up 15.7%.

The Nutrition segment includes infant formula, goat milk formula and adult nutrition products, and the protein drink Selex has reportedly passed KRW 500 billion in cumulative sales.

White milk, the core of dairy processing, has continued to post losses amid an oversupply of raw milk, and the company is partly offsetting this with growth in Greek-style fermented milk and grain beverages. In plant-based drinks, it has expanded lines of reduced-sugar soy milk and oat and almond beverages.

In infant formula, the 2023 annual report stated that the company operated 17 specialty formula products, the most among domestic makers at year-end. The company also launched Absolute Goat Milk 100 in 2025, its first new goat milk product in seven years.

Export sales rose from KRW 51.5 billion in 2022 to KRW 92.4 billion in 2025, with channel expansion centered on China and reinforcement of local production.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩471.6B₩19.9B4.2%
2025Q4₩455.1B₩14.7B3.2%
2026Q1₩469.9B₩18.8B4.0%
2026Q2₩480B₩20.4B4.3%
2026Q3₩493.7B₩22.2B4.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.7T₩60.7B₩14.4B3.6%2.9%96.2%
2023₩1.8T₩72.2B₩55B4.1%10.2%80.1%
2024₩1.8T₩70.3B₩45.5B3.9%7.9%78.4%
2025₩1.8T₩60B₩56.1B3.3%8.9%68.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Sales on the disclosed annual basis rose from KRW 1.69 trillion in 2022 to KRW 1.78 trillion in 2023 (up 5.8%), KRW 1.81 trillion in 2024 (up 1.6%) and KRW 1.84 trillion in 2025 (up 1.8%), an increase in each of the three years from 2023 to 2025, with growth slowing.

Operating profit rose from KRW 60.7 billion in 2022 to KRW 72.2 billion in 2023 (up 19.0%), the largest year in the period, before falling 2.6% to KRW 70.3 billion in 2024 and 14.7% to KRW 60 billion in 2025, a two-year decline.

The operating margin went from 3.6% in 2022 to 4.1% in 2023, 3.9% in 2024 and 3.3% in 2025, the lowest of the four years.

Margins fell while sales grew, which means cost increases outpaced the gains from higher volume, and the company and press reports cite losses in white milk and pressure from raw materials and the exchange rate.

Net profit attributable to controlling shareholders jumped from KRW 14.4 billion in 2022 to KRW 55 billion in 2023 (up 282.1%), a rise helped by the low 2022 base, before falling 17.4% to KRW 45.5 billion in 2024 and recovering 23.5% to KRW 56.1 billion in 2025.

Operating cash flow moved from -KRW 2.9 billion in 2022 to KRW 151.2 billion in 2023, then declined to KRW 74.6 billion in 2024 and KRW 51.2 billion in 2025.

The debt-to-equity ratio fell from 96.2% in 2022 to 68.9% in 2025, and at the end of 2025 total equity was KRW 631.1 billion, of which KRW 630.2 billion belonged to controlling shareholders, against total liabilities of KRW 434.8 billion.

On a quarterly basis, the fourth quarter of 2025 was the low point, with sales of KRW 455.1 billion (down 3.5% from the prior quarter) and operating profit of KRW 14.7 billion (down 26.0%).

Sales and operating profit then rose for three consecutive quarters through the third quarter of 2026, reaching KRW 493.7 billion and KRW 22.2 billion.

Net profit attributable to controlling shareholders peaked at KRW 18.8 billion in the first quarter of 2026 and then fell for two consecutive quarters, to KRW 16.2 billion and KRW 9.8 billion.

The divergence between rising operating profit and falling controlling-shareholder profit appears to come from items outside operating profit. The sum of net profit attributable to controlling shareholders over the last four quarters is KRW 60.2 billion.

05

Industry analysis

The domestic dairy industry is seeing continued losses in white milk because of an oversupply of raw milk, and rising raw material prices and exchange-rate pressure are lifting costs.

Annual per-capita milk consumption fell from 36.5 kg in 2001 to 26.2 kg in 2022, and declining births and the spread of plant-based substitutes are cited as structural factors weighing on white milk demand. Demand for premium milk such as organic and lactose-free products is reported to be comparatively steady.

In infant formula there are signs of recovery, with first-half 2026 formula sales reported up 35% year on year and goat milk formula rising by a similar rate, and the company says formula sales have also increased alongside a recent uptick in births.

The plant-based beverage market is estimated by the industry at roughly KRW 1 trillion, with reduced-sugar soy milk and oat and almond drinks driving growth. In cycle terms, white milk is in an oversupply phase, while fermented milk, nutrition and plant-based beverages are in a growth phase.

In the third quarter of 2023, dairy processing products accounted for 61.4% of the company's sales, down from 83.6% in the third quarter of 2019.

The company's position is best described by its shift in product mix, moving its center of gravity from dairy processing toward nutrition and health products, and the pace of that shift depends on how quickly white milk losses narrow.

06

Outlook

In its third-quarter 2026 results announcement, the company said it would improve profitability in existing dairy processing businesses, including white milk, and strengthen domestic and overseas competitiveness centered on Nutrition, fermented milk and grain beverages.

It said overseas operations contributed through expanded customers and restructured business operations. Export sales rose to KRW 92.4 billion in 2025 from KRW 51.5 billion in 2022, with channel expansion centered on China.

Selex is reported to average more than 120,000 units a day, and Mediwell is reported to be supplied to about 1,000 hospitals nationwide. The company spends more than KRW 10 billion a year on research and development aimed at nutrition design across age groups.

Operating profit for the first three quarters of 2026 was KRW 61.4 billion, up 35.5%, and net profit was KRW 45.1 billion, up 10.3%, according to press reports. Unlike cumulative Nutrition operating profit growth of 66.2%, the segment's third-quarter operating profit alone declined, which is a point to watch.

Whether white milk losses narrow as raw milk supply adjusts is not yet shown in disclosed data, and the trend in dairy processing operating profit in quarterly reports will show it.

The 2026 fourth-quarter and full-year results will be fixed in the 2026 annual report, and whether the operating margin rises above the 3.3% recorded in 2025 is the first marker for progress on the company's plan.

07

Valuation

PER
4.1×
PBR
0.4×
ROE
9.5%
EPS
₩8,284
BPS
₩90,876
Dividend per share
₩1,300

The share price sits in a deep discount to book value, given that controlling-shareholder equity of KRW 630.2 billion makes up nearly all of total equity of KRW 631.1 billion at the end of 2025.

On an earnings basis, the sum of net profit attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, is KRW 60.2 billion.

Annual net profit attributable to controlling shareholders varied widely, at KRW 14.4 billion in 2022, KRW 55 billion in 2023, KRW 45.5 billion in 2024 and KRW 56.1 billion in 2025, so earnings-based multiples can change considerably depending on the base year.

Operating profit fell from KRW 72.2 billion in 2023 to KRW 60 billion in 2025 but has risen each quarter in 2026, so the direction of earnings trends is mixed. Recovery in controlling-shareholder profit since 2023 has depended more on the 2025 rebound than on margin improvement.

Three factual reference points apply: the range of annual earnings swings, the 2026 quarterly profit trend, and the share price relative to book value.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Cumulative Nutrition growth

Cumulative Nutrition sales for the first three quarters of 2026 rose 15.7% to KRW 194.2 billion, and cumulative operating profit rose 66.2% to KRW 6.6 billion, according to press reports. Operating profit growth outpaced sales growth, which points to better profitability. Selex's cumulative sales passing KRW 500 billion and the recovery in formula sales support this trend.

Recovery in dairy processing profitability

Third-quarter 2026 dairy processing sales of KRW 252.4 billion rose 3.7%, while operating profit of KRW 6.4 billion rose 101.2%, according to press reports. The company said sales of Greek-style fermented milk and grain beverages offset part of the white milk losses. The segment's operating margin was reported to have risen from about 1.3% to 2.5%.

Export growth and formula recovery

Export sales grew from KRW 51.5 billion in 2022 to KRW 92.4 billion in 2025, with broader distribution in China. First-half 2026 formula sales were reported up 35%, and the company links the rise to a recent increase in births. Its 17 specialty formula products and new goat milk formula target demand for premium formula.

09

Bear factors

White milk losses and cost pressure

Raw milk oversupply continues to produce losses in white milk, and higher raw material prices and the exchange rate are adding to costs. The company itself has said that cost pressure is continuing. How far this structure weighs on earnings in the core dairy business is the main bearish consideration.

Signs of weaker earnings power

Operating profit fell from KRW 72.2 billion in 2023 to KRW 60 billion in 2025, and the operating margin dropped from 4.1% to 3.3%. Net profit attributable to controlling shareholders in the third quarter of 2026 was KRW 9.8 billion, down 38.6% year on year, and fell for two consecutive quarters. Sales have grown, but profit has not kept pace.

Slowing quarterly Nutrition profit

The Nutrition segment's third-quarter 2026 sales rose 20.1% to KRW 73.7 billion, but its operating profit fell 10.2% to KRW 2.8 billion, according to press reports. Other products' third-quarter operating profit fell 4.5% to KRW 13 billion. Whether cumulative growth carries through to quarterly results is the main test for the bearish case.

10

Risk factors

Raw milk and cost risk

If the oversupply of raw milk persists, losses in white milk could extend for longer. Higher raw material prices and exchange-rate moves also push up costs. The company has said cost pressure continues, and how quickly these costs can be passed on to prices will decide profitability.

Demographic and consumption risk

Annual per-capita milk consumption fell from 36.5 kg in 2001 to 26.2 kg in 2022. Declining births and the spread of plant-based drinks put structural pressure on white milk and formula demand. Formula sales have reportedly recovered recently, but whether that holds depends on the birth trend.

Overseas and business transition execution risk

Exports are reported to depend heavily on China, making the business sensitive to local distribution and customer changes. If quarterly profit in growth categories such as Nutrition and fermented milk wavers, the pace of the business transition could slow.

Overseas sales remain a small share of the total, so they are unlikely to determine consolidated results on their own.

11

What to watch next

  1. Late March 2027

    Submission of the 2026 annual report. The checkpoints are whether the 2026 operating margin rises above 3.3% from 2025 and whether net profit attributable to controlling shareholders exceeds KRW 56.1 billion.

  2. By May 15, 2027

    Deadline for the first-quarter 2027 quarterly report. The checkpoints are the trend in white milk losses and whether Nutrition's quarterly operating profit recovers from its third-quarter 2026 decline.

  3. By August 14, 2027

    Deadline for the second-quarter 2027 quarterly report. The checkpoints are whether the run of rising sales and operating profit continues and whether the decline in net profit attributable to controlling shareholders stops.

  4. First half of 2027 (date not set)

    Industry-wide changes in raw milk supply and pricing. These external factors will determine whether white milk losses narrow.

12

Overall view

Maeil Dairies' sales of KRW 493.7 billion and operating profit of KRW 22.2 billion in the third quarter of 2026 both rose year on year, and sales and operating profit have risen for three straight quarters.

However, net profit attributable to controlling shareholders fell 38.6% to KRW 9.8 billion in the same quarter and has declined for two consecutive quarters.

On an annual basis, operating profit fell from KRW 72.2 billion in 2023 to KRW 60 billion in 2025, and the operating margin of 3.3% in 2025 was the lowest of the four years. Positive factors include cumulative Nutrition growth, the recovery in dairy processing profit, the rebound in formula sales and export expansion.

Negative factors include white milk losses, cost pressure, declining white milk demand tied to low births, and the third-quarter decline in standalone Nutrition operating profit.

The share price sits at a deep discount to book value, but annual net profit attributable to controlling shareholders has varied widely, so earnings-based multiples can be read in many ways.

The 2026 annual report is due by late March 2027, and the direction of the operating margin and controlling-shareholder profit at that point will be the most important test. This report is for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. dailian.co.kr
  2. dailypop.kr
  3. sateconomy.co.kr
  4. insightkorea.co.kr
  5. mydaily.co.kr
  6. supple.kr
  7. ddaily.co.kr
  8. ziksir.com
  9. foodnews.co.kr
  10. maeil.com
  11. ilemonde.com
  12. mediapen.com
  13. sisajournal-e.com
  14. goinsider.kr
  15. fntimes.com
  16. thevc.kr
  17. munhwa.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis